Tag Archives: AACR

Poseida, Caribou, and Takeda Presented Data for Hematological Malignancies; AACR 2024 Analysis 2

AACR 2024 Analysis 2: Poseida, Caribou, and Takeda presented clinical and preclinical updates from their programs in hematological malignancies. Below, Celltelligence provides insights and key context for selected presentations. The following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Reports Updated Results from ALLO-316 in Renal Carcinoma; AACR 2023 Analysis 2

AACR 2023 Analysis 2: Allogene reported updated clinical data from its Ph1 TRAVERSE trial evaluating ALLO-316 (allogeneic CD70 CAR-T) in clear cell renal carcinoma (ccRCC). Below, Celltelligence provides insights on the clinical data from ALLO-316 in ccRCC while discussing potential strategies that Allogene could develop to improve ALLO-316 potency in solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Different Strategies for Enhancing CAR-Ts to Treat Solid Tumors; Preclinical Results from Allogene’s ALLO-316; TCR2 Tx’s Allogeneic TRuC-T Platform; AACR 2022 Analysis 4

AACR 2022 Analysis 4: Several key cell therapy-related topics were discussed to overcome the challenges associated with utilizing CAR-Ts for solid tumors. Additionally, preclinical results were presented from Allogene and TCR2 Tx. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

How Engineered CAR-NK Cells Could Overcome Several Major Challenges Faced by CAR-Ts; Nkarta and CRISPR Tx Report Preclinical Data for Developing a CD70 CAR-NK and a NK:T Treatment; AACR 2022 Analysis 1

AACR 2022 Analysis 1: Several preclinical and clinical updates were presented describing potential strategies to overcome key hurdles associated with NK-based cell therapies. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.